Shionogi launches novel antibiotic Fetcroja in the UK
The drug is indicated for use as a treatment of infections caused by aerobic Gram-negative bacteria
Read More
Tag: Fetcroja
EC approves Shionogi’s new antibiotic Fetcroja
Fetcroja is the first treatment to provide coverage against all Gram-negative pathogens considered of critical priority
Read More
CHMP recommends just two new meds in Feb meeting
The committee also noted three extensions of pre-existing therapies.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
